ASCR Laboratory Membership
| Penn Lab - Cleveland Clinic, Cleveland, OH |
 |
 |
 |
|
Penn Lab - Cleveland Clinic Mission: Identification and optimization of molecular pathways involved in myocardial repair in order to optimize cardiac function and improve patient outcomes. Director: Marc Penn, MD, PhD
Background of Director: Dr. Marc Penn is a staff cardiologist in the Department of Cardiovascular Medicine. He is Director of the Bakken Heart-Brain Institute at the Cleveland Clinic. He is also the Medical Director of Coronary Intensive Care Unit, Director of the Experimental Cardiology Laboratory and Associate Director of the Cardiovascular Medicine Fellowship in the Departments of Cardiovascular Medicine, Cell Biology and Biomedical Engineering. Dr. Penn is board certified in Internal Medicine and Cardiovascular Medicine. He has a special interest in myocardial ischemia, vascular biology, cardiac critical care and stem cell and gene therapy for the regeneration and recovery of myocardial function. Dr. Penn completed his undergraduate and post graduate work at Case Western Reserve University earning honors on his way to completing a Ph.D. in Biomedical Engineering. Dr. Penn earned his medical degree from Case Western Reserve University School of Medicine. He completed his Internal Medicine training at University Hospitals of Cleveland before being offered a Fellowship to the Cleveland Clinic Foundation Department of Cardiology. He joined the professional staff of Cleveland Clinic Foundation in July of 2000. Dr. Penn’s education and training have helped him in developing drug delivery systems for the treatment of cardiovascular disease, including studies to optimize gene therapy and stem cell therapy for the regeneration of myocardial tissue from which several patents are pending. Dr. Penn has an academic appointment at Case Western Reserve University in the Department of Biomedical Engineering and the Bioengineering Center at Cleveland State University. He is recipient of the 2000 Joseph Cash Memorial Prize for Clinical Outcomes Research and the 1999 Irvine H. Page Young Investigator award presented by the National American Heart Association, among others. He is the recipient of a number of research grants from the American Heart Association and National Institutes of Health. In 2001, Dr. Penn was named director of the Experimental Cardiology Laboratory in the Department of Cardiovascular Medicine at the Cleveland Clinic. This laboratory is dedicated to the discovery and implementation of novel drug and gene therapies, as well as devices for the treatment of cardiovascular disease in clinical populations. Dr. Penn has been an invited lecturer at international symposiums and conferences and is author or co-author of numerous published articles, abstracts, book chapters and books on a wide range of topics, including the effects of lipoprotein oxidation and lipoprotein-induced cell injury in diabetes; mechanism of clot formation in atherosclerotic arteries, optimal management of patients with acute aortic dissection, and stem cell and gene based therapies for acute myocardial infarction and heart failure. His book entitled Stem Cells and Myocardial Regeneration published by Humana Press was released in October, 2006. Dr. Penn is an active inventor, and is named on several patent applications under review, including several in the area of stem cell based therapies for the treatment of chronic heart failure. He is the founder of RegenRx Medical Systems, a stem cell based myocardial therapeutics company founded on intellectual property developed in his laboratory. He is co-founder of Prognostix, Inc, a diagnostic company based on biomarkers associated with coronary artery disease, myocardial infarction and other inflammatory diseases. He serves on the Scientific Advisory Boards Frantz Medical Ventures (New York City) and Oakwood Medical Ventures (St. Louis, MO). He received the Innovator of the Year Award of the Cleveland Clinic in 2006. Dr. Penn is currently the President of the Cleveland Metro Division of the American Heart Association, and a member of the Cleveland board of the American Technion Society. Current Projects:
|
